The DOI matches its Crossref record; 235 of the 239 references it cites were found in a registry or an index.
Transgenic mouse models of alzheimer disease: Developing a better model as a tool for therapeutic interventions.
Open accessAbstract
Alzheimer disease (AD) is the leading cause of dementia among elderly. Currently, no effective treatment is available for AD. Analysis of transgenic mouse models of AD has facilitated our understanding of disease mechanisms and provided valuable tools for evaluating potential therapeutic strategies. In this review, we will discuss the strengths and weaknesses of current mouse models of AD and the contribution towards understanding the pathological mechanisms and developing effective therapies. Keywords: Alzheimer disease, amyloid-beta, tau, transgenic mouse models, dementia, neurodegeneration, amyloid precursor protein (APP), mild cognitive impairment (MCI), synaptic dysfunction, mutations
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“transgenic animal models are an invaluable tool for studying pathogenic mechanisms and testing therapeutics of AD (Kitazawa et al., 2012; Jankowsky and Zheng, 2017; Sasaguri et al., 2017).”
From Age-dependent microstructure alterations in 5xFAD mice by high-resolution diffusion tensor imaging (2022) · cites this paper as Kitazawa et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“Tg2576 mice also produce oligomeric A , which seems to be more toxic than fibrillar or aggregated A in plaques [45].”
BackgroundRetractedGlobal prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M. J., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K. S., Hasegawa, K., Hendrie, H. C., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,336
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Self-citationCorrelative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
A protein factor essential for microtubule assembly
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., & Kirschner, M. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.5.1858 · Cited by 3,089
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Cited by
Sorted by citations
Items 101–179 of 179
Habiba, U., Ozawa, M., CHAMBERS, J. K., Uchida, K., Descallar, J., Nakayama, H., Summers, B. A., Morley, J. W., & Tayebi, M. (2021) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210035 · Cited by 20
Sanna, P. P., Cabrelle, C., Kawamura, T., Mercatelli, D., O’Connor, N., Roberts, A. J., Repunte‐Canonigo, V., & Giorgi, F. M. (2023) · eNeuro · doi:10.1523/eneuro.0456-22.2023 · Cited by 17
Yeapuri, P., Machhi, J., Foster, E. G., Kadry, R., Bhattarai, S., Lu, Y., Sil, S., Sapkota, R., Srivastava, S., Kumar, M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70084 · Cited by 15
Reproducible differentiation and characterization of neurons from mouse embryonic stem cells
Saxena, S., Choudhury, S., & Mohan, K. N. (2020) · MethodsX · doi:10.1016/j.mex.2020.101073 · Cited by 15
Imm, J. L., Kerrigan, T. L., Jeffries, A. R., & Lunnon, K. (2017) · Epigenomics · doi:10.2217/epi-2017-0076 · Cited by 14
Geroprotective interventions in the 3xTg mouse model of Alzheimer’s disease
Sonsalla, M. M., & Lamming, D. W. (2023) · GeroScience · doi:10.1007/s11357-023-00782-w · Cited by 17
Jeyaraman, M., Rajendran, R. L., Muthu, S., Jeyaraman, N., Sharma, S., Jha, S. K., Muthukanagaraj, P., Hong, C. M., da Fonseca, L. F., Lana, J. F., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17808 · Cited by 15
Advances in Stem Cell Therapy for Huntington’s Disease: A Comprehensive Literature Review
Shah, S., Mansour, H. M., & Lucke-Wold, B. P. (2025) · Cells · doi:10.3390/cells14010042 · Cited by 16
Uddin, M. S., Kabir, M. T., Mamun, A. A., Behl, T., Mansouri, R. A., Aloqbi, A. A., Perveen, A., Hafeez, A., & Ashraf, G. M. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200531151004 · Cited by 16
Lim, J. Y., Lee, J. E., Park, S. A., Park, S., Yon, J.-M., Park, J.-A., Jeun, S., Kim, S. J., Lee, H. J., Kim, S. W., et al. (2022) · Cells · doi:10.3390/cells11061029 · Cited by 15
Current concepts in Alzheimer’s Disease: molecules, models and translational perspectives
Rutten, B. P. F., & Steinbusch, H. W. M. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-33 · Cited by 15
Kiss, É., Kins, S., Gorgas, K., Szakács, K. H. V., Kirsch, J., & Kuhse, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084165 · Cited by 14
Paganetti, P., Antoniello, K., Devraj, K., Toni, N., Kieran, D., Madani, R., Pihlgren, M., Adolfsson, O., Froestl, W., Schrattenholz, A. S., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-131091 · Cited by 13
den Broeck, L. V., Sierksma, A. S. R., Hansquine, P., Thonnard, D., Callaerts‐Vegh, Z., & D’Hooge, R. (2020) · Genes Brain & Behavior · doi:10.1111/gbb.12695 · Cited by 14
King, J. L., Wong, A. A., & Brown, R. E. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170805 · Cited by 13
Zolezzi, J. M., Lindsay, C. B., Serrano, F. G., Ureta, R. C., Theoduloz, C., Schmeda‐Hirschmann, G., & Inestrosa, N. C. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170701 · Cited by 12
Age-dependent microstructure alterations in 5xFAD mice by high-resolution diffusion tensor imaging
Maharjan, S., Tsai, A. P., Lin, P. B., Ingraham, C., Jewett, M. R., Landreth, G. E., Oblak, A. L., & Wang, N. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.964654 · Cited by 15
“Despite the knowledge gained from human studies, transgenic animal models are an invaluable tool for studying pathogenic mechanisms and testing therapeutics of AD (Kitazawa et al., 2012; Jankowsky and Zheng, 2017; Sasaguri et al., 2017).”
BackgroundRat models of major neurodegenerative disorders
Novati, A., Singer, E., Yu-Taeger, L., Clemensson, E. K. H., & Nguyen, H. P. (2022) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2022.19 · Cited by 10
Inflammation in Alzheimer’s disease: A friend or foe?
Chiroma, S. M., Baharuldin, M. T. H., Taib, C. N. M., Amom, Z., Jagadeesan, S., & Moklas, M. A. M. (2018) · Biomedical Research and Therapy · doi:10.15419/bmrat.v5i8.464 · Cited by 11
Rao, C. V., Farooqui, M., Asch, A. S., & Yamada, H. Y. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1515554 · Cited by 11
Retinal Changes in Transgenic Mouse Models of Alzheimer’s Disease
Guo, L., Ravindran, N., Shamsher, E., Hill, D., & Cordeiro, M. F. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210414113634 · Cited by 13
Animal models of cognitive aging and circuit-specific vulnerability
Burke, S. N., & Foster, T. C. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804766-8.00002-9 · Cited by 11
Adak, S., Singh, S., Jain, R., Tiwari, A., Singh, B., Kumar, S., Dadhwal, A., Chakroborty, A., Sharma, A. K., Singh, R. P., et al. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1646551 · Cited by 12
Sex-Related Motor Deficits in the Tau-P301L Mouse Model
Camargo, L. C., Honold, D., Bauer, R., Shah, N. J., Langen, K., Willbold, D., Kutzsche, J., Willuweit, A., & Schemmert, S. (2021) · Biomedicines · doi:10.3390/biomedicines9091160 · Cited by 9
Cognitive trajectories in longitudinally trained 3xTg-AD mice
Duggan, M. R., Steinberg, Z. R., Peterson, T., Francois, T.-J., & Parikh, V. (2023) · Physiology & Behavior · doi:10.1016/j.physbeh.2023.114435 · Cited by 8
A Novel Form of Compensation in the Tg2576 Amyloid Mouse Model of Alzheimer’s Disease
Somogyi, A., Katonai, Z., Alpár, A., & Wolf, E. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00152 · Cited by 7
Ullah, R., Ali, G., Khan, A., Ahmad, S., & Al-Harrasi, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179559 · Cited by 5
Misfolded proteins as a therapeutic target in Alzheimer's disease
Liyanage, S. I., & Weaver, D. F. (2019) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2019.08.003 · Cited by 8
An Overview of Transgenic Mouse Models for the Study of Alzheimer’s Disease
Lopes, P. A., Pádua, M. S., & Guil‐Guerrero, J. L. (2025) · Journal of dementia and Alzheimer's disease · doi:10.3390/jdad2010002 · Cited by 9
Recent Trends in Nano-Particulate Carriers for the Diagnosis and Treatment of Alzheimer’s Disease
Yadav, A. K., & Mazahir, F. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220420133059 · Cited by 6
Salem, H., Rocha, N. P., Colpo, G. D., & Teixeira, A. L. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160250 · Cited by 6
The influence of aging and the microbiome in multiple sclerosis and other neurologic diseases
Fettig, N. M., Pu, A., Osborne, L. C., & Gommerman, J. L. (2024) · Immunological Reviews · doi:10.1111/imr.13361 · Cited by 7
Amyloid beta 1–42-induced animal model of dementia
Budni, J., & de Oliveira, J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815868-5.00054-2 · Cited by 4
EBP1 potentiates amyloid β pathology by regulating γ-secretase
Kim, B.-S., Hwang, I., Ko, H. R., Kim, Y. K., Kim, H. J., Seo, S. W., Choi, Y., Lim, S., Kim, Y. K., Nie, S., et al. (2025) · Nature Aging · doi:10.1038/s43587-024-00790-1 · Cited by 4
How efficient are rodent models for Alzheimer’s disease drug discovery?
Guo, B., & Zhou, Q. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1398730 · Cited by 4
Naffaa, M. M. (2025) · Lifespan development and mental health. · doi:10.70322/ldmh.2025.10005 · Cited by 3
Rodent Models of Alzheimer’s Disease
Singh, A., Ghosh, S., Singh, D. K. K., Yarlagadda, B., & Sinha, J. K. (2026) · Contemporary clinical neuroscience · doi:10.1007/978-3-032-18296-8_13 · Cited by 3
Rationale for Curcumin Therapy in Alzheimer’s Disease
(2016) · ARC Journal of Neuroscience · doi:10.20431/2456-057x.0103002 · Cited by 3
The role of proteotoxic stress in vascular dysfunction in the pathogenesis of Alzheimer’s disease
Fonseca, A. C. R. G., Resende, R., Cardoso, S. M., & Pereira, C. (2015) · Endoplasmic Reticulum Stress in Diseases · doi:10.1515/ersc-2015-0005 · Cited by 3
QTC-4-MeOBnE Ameliorated Depressive-Like Behavior and Memory Impairment in 3xTg Mice
Fronza, M. G., Sacramento, M., Alves, D. A. C., Praticò, D., & Savegnago, L. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03159-w · Cited by 3
Jiang, Z., Qin, Y., Luo, B., Bai, F., Liu, J., Ma, L., He, S., Chen, R., Wang, Y., Liu, S., et al. (2026) · Advanced Science · doi:10.1002/advs.202520239 · Cited by 3
Quach, B., Salehi, S. N., Roufegarinejad, R., Guleria, V. S., Mante, M., Florio, J. B., Rissman, R. A., & Winston, C. N. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.115893 · Cited by 2
Animal models for Alzheimer's disease – the industry perspective
Czech, C., & Grueninger, F. (2013) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2013.07.001 · Cited by 3
Andriana, K., Aulia, I., & ., R. (2023) · KnE Medicine · doi:10.18502/kme.v3i2.13051 · Cited by 2
Rentsch, P., Ganesan, K., Langdon, A., Konen, L. M., & Vissel, B. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1421900 · Cited by 3
Regulation of Caenorhabditis Elegans model in Alzheimer’s Disease
Jing, Y. (2020) · E3S Web of Conferences · doi:10.1051/e3sconf/202018503043 · Cited by 2
Transcription Factor-Mediated Differentiation of Human iPSCs into Neurons v1Preprint
Fernandopulle, M. S., Prestil, R., Grunseich, C., Wang, C., Gan, L., & Ward, M. E. (2019) · doi:10.17504/protocols.io.54rg8v6 · Cited by 1
Dube, K., Stoinescu, A., & Pandey, S. (2026) · Nutrients · doi:10.3390/nu18121986 · Cited by 1
Verdier, J., & Mestre‐Francés, N. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781139871822.008 · Cited by 1
Gorina, Y. V., Власова, О. Л., Bolshakova, A. V., & Salmina, A. B. (2023) · Российский физиологический журнал им И М Сеченова · doi:10.31857/s0869813923010065 · Cited by 1
Sung, K.-C., Wang, L.-Y., Wang, C.-C., Chu, C., Sun, H. S., & Hsiao, Y. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00623-3 · Cited by 1
Sex and the Aging Immune System
Gibson, D. C., & Bupp, M. G. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811353-0.00059-2 · Cited by 1
Fukuchi, K., Yang, J., Kou, J., Song, M., Lalonde, R., Planque, S. A., & Paul, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809813-4.00006-5 · Cited by 1
Naha, N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820595-2.00014-x · Cited by 1
Synaptic modifications in hippocampal CA3 pyramidal cells in an Alzheimer's mouse model
Zhang, P. (2018) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-6752 · Cited by 1
Transgenic Mice and Pluripotent Stem Cells Express EGFP under the Control of miR-302 PromoterPreprint
Rahimi, K., Parsa, S., Nikzaban, M., Mowla, S. J., & Fathi, F. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/450791 · Cited by 1
Induction and prevention of patterned neurodegeneration by amyloid precursor protein
Crisp, A. (2013) · Texas ScholarWorks (Texas Digital Library)
Genetic Screens in Neurodegeneration
Acevedo‐Arozena, A., & Corrochano, S. (2017) · Wiley eBooks · doi:10.1002/9781118540770.ch1
Phillips, E. C. (2017) · Research Portal (King's College London)
Hettinger, J. C. (2017) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7jq10fn
Amyloid Precursor Protein (APP) processing and potential targets for Alzheimer’s Disease
Bonner, A. B. (2019) · Biomedical Genetics and Genomics · doi:10.15761/bgg.1000146
Strain-specific profiling of Amyloid-β in Alzheimer´s disease: functional and clinical signature
Noor, A. (2020) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7997
Nguyen, P., Kim, A., & Koh, Y. H. (2021) · Microscopy Research and Technique · doi:10.1002/jemt.24007
Gorina, Y. V., Salmina, A. B., Chernyuk, D., Bolshakova, A. V., Balaban, P. M., Борисович, Б. И., & Власова, О. Л. (2022) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-022-01301-8
Gorina, Y. V., Власова, О. Л., Bolshakova, A. V., & Salmina, A. B. (2023) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093023010106
Advancing Neurodegenerative Disease Research
Bouazzaoui, F., Jaouhari, Y., hatimy, O. E., Azraida, H., Kabdy, H., Badaoui, M., Moubtakir, S., Yazouli, L. E., Aboufatima, R., Loukid, M., et al. (2026) · IGI Global eBooks · doi:10.4018/979-8-3373-1365-8.ch015
Sepulveda-Diaz, J. E. (2013) · theses.fr (ABES) · doi:10.70675/56c42bcbz41dfz432bzbb78z77110b373285
Revealing subcellular retinal alterations in 5xFAD B6SJLF1/J mice
Giani, A., Musi, C. A., Priori, E. C., Turchetti, S., Passi, M., Galbiati, S., Viganò, I., Bakker, N., Klaassen, I., Zerbini, G., et al. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.115758
Synaptic modifications in hippocampal CA3 pyramidal cells in an Alzheimer's mouse model
Zhang, P. (2017) · theses.fr (ABES) · doi:10.70675/74cb83e0z6db8z4bb5z838dz6e1bb1c6275f
Souchet, B. (2018) · theses.fr (ABES) · doi:10.70675/5510ef76zecf1z41f2z9496z015aa6a093be
Haddjeri-Hopkins, A. (2019) · theses.fr (ABES) · doi:10.70675/a38a5613zb413z4383z8a01z7a02dca49b6b
Advances and Limitations of Rodent Models in Alzheimer’s Disease Pathogenesis and Therapeutics
Singh, A., & Duerner, L. (2026) · Science Discovery Medicine · doi:10.11648/j.sdmed.20260102.14
CRISPR-Cas-Based Editing Technologies in Preclinical Models for Disease Correction
Karki, P., & Sudarshan, G. C. (2026) · Genetics. · doi:10.5772/intechopen.1015771 · Cited by 1
Mittli, D., & Pahnke, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.28.741021
Structural insights into pathological protein aggregates: from amyloid fibrils to inclusion bodies
Bej, A., Mandal, N., Das, A., & Nandi, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36636-9.00002-2
Metadata
- Authors
- Kitazawa, M., Medeiros, R., & M. LaFerla, F.
- Affiliations
- University of California, Merced (US)
- University of California, Irvine (US)
- Corresponding author
- Kitazawa, Masashi
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-03-01
- Volume
- 18
- Issue
- 8
- Pages
- 1131-1147
- ISSN
- 1381-6128 (ISSN-L)
- PMC
- PMC4437619
- OpenAlex
- W2095268222
- Cited by
- 178
- References
- 239
- Citations by year
- 2026: 10 · 2025: 8 · 2024: 12 · 2023: 17 · 2022: 13 · 2021: 17 · 2020: 20 · 2019: 18 · 2018: 25 · 2017: 10 · 2016: 8 · 2015: 6 · 2014: 6 · 2013: 7 · 2012: 1
- FWCI
- 0.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Current Pharmaceutical Design (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- National Institute on Aging (R01AG021982)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, transgenic mouse model, amyloid-beta, tau protein, amyloid precursor protein, mild cognitive impairment, synaptic dysfunction, neurodegeneration, dementia, therapeutic interventions, APP mutations
- MeSH terms
- Aged, Alzheimer Disease, Animals, Disease Models, Animal, Humans, Mice, Transgenic, Drug Design, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
